Acorda Therapeutics is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Co. markets Inbrija (levodopa inhalation powder), which is approved for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as needed use and utilizes Co.'s ARCUS pulmonary delivery system. Co. also markets branded Ampyra (dalfampridine), extended release tablets, 10 mg for improving walking in people with multiple sclerosis. Co.'s ARCUS development has been focused on a program for acute treatment of migraine. The ACOR stock yearly return is shown above.
The yearly return on the ACOR stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2015 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ACOR annual return calculation with any dividends reinvested as applicable (on ex-dates).
|